Salts and solid forms of (r)-1-(5-methoxy-1h-indol-1-yl)-n,n-dimethylpropan-2-amine

Abstract

The present disclosure is directed to salt and solid forms of (R)-1-(5-METHOXY-1H-INDOL-1-YL)-N,N-DIMETHYLPROPAN- 2 -AMINE and methods of treating neurological disorder and/or a psychiatric disorder in a subject in need thereof.

1 . A (R)-1-(5-methoxy-1H-indol-1-yl)-N,N-dimethylpropan-2-amine, compound 1) salt. 
     
     
         2 . The compound 1 salt of  claim 1 , wherein the salt is crystalline. 
     
     
         3 . The compound 1 salt of  claim 1 , wherein the salt is amorphous. 
     
     
         4 . The compound 1 salt of  claim 1 , wherein the salt is a fumarate, monofumarate salt or hemi-fumarate salt. 
     
     
         5 .- 69 . (canceled) 
     
     
         70 . The compound 1 salt of  claim 1 , wherein the salt is a HCl salt. 
     
     
         71 .- 91 . (canceled) 
     
     
         92 . The compound 1 salt of  claim 1 , wherein the salt is a maleate salt. 
     
     
         93 .- 102 . (canceled) 
     
     
         103 . The compound 1 salt of  claim 1 , wherein the compound 1 salt is a benzoate salt. 
     
     
         104 .- 113 . (canceled) 
     
     
         114 . The compound 1 salt of  claim 1 , wherein the compound 1 salt is a tosylate salt. 
     
     
         115 .- 124 . (canceled) 
     
     
         125 . The compound 1 salt of  claim 1 , wherein the compound 1 salt is a tartrate salt. 
     
     
         126 .- 135 . (canceled) 
     
     
         136 . The compound 1 salt of  claim 1 , wherein the compound 1 salt is an HBr salt. 
     
     
         137 .- 146 . (canceled) 
     
     
         147 . The compound 1 salt of  claim 1 , wherein the compound 1 salt is a galactarate salt. 
     
     
         148 .- 155 . (canceled) 
     
     
         156 . The compound 1 salt of  claim 1 , wherein the compound 1 salt is a succinate salt. 
     
     
         157 .- 164 . (canceled) 
     
     
         165 . The compound 1 salt of  claim 1 , wherein the compound 1 salt is a citrate salt. 
     
     
         166 .- 173 . (canceled) 
     
     
         174 . The compound 1 salt of  claim 1 , wherein the compound 1 salt is a malate salt. 
     
     
         175 .- 182 . (canceled) 
     
     
         183 . The compound 1 salt of  claim 1 , wherein the compound 1 salt is a glucuronate salt. 
     
     
         184 .- 191 . (canceled) 
     
     
         192 . The compound 1 salt of  claim 1 , wherein the compound 1 salt is an ascorbate salt. 
     
     
         193 .- 200 . (canceled) 
     
     
         201 . The compound 1 salt of  claim 1 , wherein the compound 1 salt is a sulfate salt. 
     
     
         202 . The compound 1 salt of  claim 1 , wherein the compound 1 salt is a mesylate salt. 
     
     
         203 . The compound 1 salt of  claim 1 , wherein the compound 1 salt is an esylate salt. 
     
     
         204 . The compound 1 salt of  claim 1 , wherein the compound 1 salt is a phosphate salt. 
     
     
         205 . (canceled) 
     
     
         206 . The compound 1 salt of  claim 1 , wherein the compound 1 salt is an edsylate salt. 
     
     
         207 . The compound 1 salt of  claim 1 , wherein the compound 1 salt is an adipate salt. 
     
     
         208 . A pharmaceutical composition comprising the compound 1 salt of  claim 1  and a pharmaceutically acceptable excipient. 
     
     
         209 . A method of treating a brain disorder, a neurological disorder and/or a psychiatric disorder in a subject in need, comprising administering to the subject a salt of  claim 1 . 
     
     
         210 - 211 . (canceled)